AMGEN INC — Director's Dealing 2023

Sep 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Neumora Therapeutics, Inc. (NMRA)
CIK: 0001885522
Period of Report: 2023-09-19

Reporting Person: AMGEN INC (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-19	Common Stock	C	33603948	—	Acquired	33603948	Direct
2023-09-19	Common Stock	P	1764705	$17	Acquired	35368653	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-19	Series A-2 Preferred Stock	$	C	32754291	Disposed		Common Stock (32754291)	Direct
2023-09-19	Series B Preferred Stock	$	C	849657	Disposed		Common Stock (849657)	Direct

Footnotes

F1: The shares of Series A-2 Preferred Stock and Series B Preferred Stock of the Issuer automatically converted on a 1-for-1 basis into Common Stock of the Issuer immediately prior to the closing of the Issuer's initial public offering.